Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FOSL2 CUT-tag analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

ABSTRACT: FOSL2 CUT-tag analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

PROVIDER: PRJNA788917 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17259632_1.fastq.gz	Fastqsanger.gz
	SRR17259632_2.fastq.gz	Fastqsanger.gz
	SRR17259633_1.fastq.gz	Fastqsanger.gz
	SRR17259633_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

FOSL2 CUT-tag analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

Project description:We profile FOSL2 genome occupancy upon KPC mice of pancreatic cancer

2022-12-20 | GSE190912 | GEO

ATAC-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

Project description:ATAC-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

| PRJNA788897 | ENA

H3K27ac ChIP-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

Project description:H3K27ac ChIP-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

| PRJNA788904 | ENA

RNA-Seq of genetically engineered mouse models (GEMMs) of PDA with or without KRAS and/or TP53 mutations

Project description:RNA-Seq of genetically engineered mouse models (GEMMs) of PDA with or without KRAS and/or TP53 mutations

| PRJNA788916 | ENA

Expression data from genetically engineered mouse models (GEMMs)

2013-07-02 | GSE39557 | GEO

Expression data from genetically engineered mouse models (GEMMs)

Project description:3 Cell lines from Apc, p53 (AP) GEMMs were compared to 12 cell lines from Apc, Kras, p53 (AKP) GEMMs. Mouse 430 2.0 arrays were used to determine genomic expression differences between the two genotypes (AP and AKP). RNA was extracted from 3 AP and 10 AKP cell lines using the Qiagen RNEasy kit, and hybridized to individual Affymetrix mouse 430 2.0 chips as per manufacturer's instructions

2013-07-02 | E-GEOD-39557 | biostudies-arrayexpress

ATAC-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

Project description:We profile chromatin accessibility signals in WT, KC and KPC mice of pancreatic cancer

2022-12-20 | GSE190900 | GEO

RNA-seq of intestinal cancer GEMMs

Project description:Intestinal tumours from genetically engeenierd mouse modesl (GEMMs), of various gentopyes, were isolated at endpoint and RNA was isolated. In an additional experiment, epithelial tumour organoids were isolated at end point and grown in vitro. These organoids were harvested 72 hours after seeding and RNA was isolated.

2019-09-16 | E-MTAB-6363 | biostudies-arrayexpress

Predicting drug responsiveness in humans cancers using genetically engineered mice

Project description:Anti-cancer drug testing is challenging, but genetically engineered mouse models (GEMMs) and orthotopic, syngeneic transplants (OSTs) may offer advantages for pre-clinical testing including an intact microenvironment. We examined the efficacy of six chemotherapeutic or targeted anti-cancer drugs, alone and in combination, using over 500 GEMMs/OSTs representing three distinct breast cancer subtypes: Basal-like (C3(1)-T-antigen GEMM), Luminal B (MMTV-Neu GEMM), and Claudin-low (T11/TP53-/- OST). While a few single agents offered exceptional efficacy like lapatinib in the Neu/ERBB2 driven model, combination therapies tended to be more active and life prolonging. Using expression profiling of chemotherapy treated murine tumors, we identified an expression signature that was able to predict pathological complete response to neoadjuvant anthracycline-taxane treated human breast cancer patients, even after accounting for the common clinical variables and other genomic signatures. These results show that credentialed murine models can predict the efficacy of would-be anti-cancer compounds in humans, and that GEMMs can be used to develop new biomarkers of therapeutic responsiveness in humans. control X treatment

2014-01-01 | E-GEOD-37915 | biostudies-arrayexpress

H3K27ac ChIP-seq analysis of genetically engineered mouse models (GEMMs) of PDA with KRAS and TP53 mutations

Project description:We profile H3K27ac signals in WT, KC and KPC mice of pancreatic cancer

2022-12-20 | GSE190901 | GEO